SCHEMBL8300121

SCHEMBL8300121

O=C(Nc1cccnc1)C(=O)c1ccc(OC(F)F)c2oc3ccccc3c12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 6/20 0.47
PDE4D Q08499 5/20 0.45
PDE4A P27815 4/20 0.45
PDE4C Q08493 4/20 0.45
KDM4E B2RXH2 4/20 0.44
NPC1 O15118 5/20 0.41
RAB9A P51151 3/20 0.41
PKM P14618 1/20 0.41
HSD17B10 Q99714 4/20 0.40
MAPT P10636 3/20 0.40
HPGD P15428 3/20 0.40
POLB P06746 2/20 0.40
TP53 P04637 1/20 0.40
ALOX15 P16050 1/20 0.40
NFKB1 P19838 1/20 0.40
NFKB2 Q00653 1/20 0.40
RELA Q04206 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
HTT P42858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5023292 0.90 PDE4D (0.51) PDE4BPDE4DPDE4APDE4CKDM4E
SCHEMBL8298298 0.89 PDE4B (0.47) PDE4BPDE4DPDE4APDE4CKDM4E
SCHEMBL8301499 0.87 NPC1 (0.46) PDE4BPDE4DPDE4APDE4CKDM4E
SCHEMBL8302112 0.85 NPC1 (0.46) NPC1RAB9APKMMAPTPOLB
SCHEMBL8298185 0.84 PDE4A (0.46) PDE4BPDE4DPDE4APDE4CKDM4E
SCHEMBL8298827 0.83 PDE4B (0.64) PDE4BPDE4DPDE4APDE4CKDM4E
SCHEMBL5018001 0.82 LRRK2 (0.51) PDE4DKDM4ENPC1RAB9AHSD17B10
SCHEMBL5026501 0.79 PDE4D (0.51) PDE4BPDE4DPDE4APDE4CKDM4E
SCHEMBL5022678 0.79 KDM4E (0.49) PDE4BPDE4DPDE4APDE4CKDM4E
SCHEMBL8301408 0.78 PDE4B (0.45) PDE4BPDE4DPDE4APDE4CKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2004111044-A1 TRICYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS:PROCESS FOR THEIR PREPARATION GLENMARK PHARMACEUTICALS LTD. (US) 2004-12-23 WO disclosed